Tema Oncology ETF

*Potentially incorrect data identified

CANC
ETF Ticker

+17.17%

+34.80%

NASDAQ

Equity

Global

Thematic

The Tema Oncology ETF, CANC_US, is an actively managed strategy providing exposure to Global, Thematic Equity. It is listed on the NASDAQ and has assets under management of $210.0m (as of Aug 31, 2026). The ETF trades in USD and was listed on the exchange on Aug 15, 2023. It has a net expense ratio of 75bps. (All data in USD as of Oct 15, 2026 unless stated.)

The investment strategy underpinning the actively managed Tema Oncology ETF governs an equity portfolio focused on companies deriving ≥50% of revenues from oncology across therapeutics, diagnostics, devices, and cancer-focused services, with an expected U.S. and Europe emphasis. The investable universe requires market cap ≥ USD 100 million and three-month ADV ≥ USD 500,000 to support ongoing liquidity and capacity; the portfolio is non-diversified and typically holds >15 but <100 names with position sizes reflecting conviction, liquidity and downside risk. Security selection relies on internal fundamental research of disclosures and other public sources to assess clinical, commercial, and competitive positioning; holdings are monitored for revenue-source eligibility and economic durability. The fund does not hedge currencies and may hold foreign currency incidentally for settlement. Rebalancing and trims reflect valuation discipline, pipeline or reimbursement inflections, or loss of oncology revenue qualification; additions prioritize clear oncology revenue linkage and tradability.

ETF Details

Key Facts

Issuer:
Tema
AUM:
$210.0m (as of Aug 31, 2026)
Net Expense Ratio:
75 bps
Inception Date:
Aug 15, 2023
Index:
Actively managed strategy
Dividend Frequency:
N/A

Trading

Ticker:
CANC
Exchange:
NASDAQ
ISIN:
US87975E7013
Trading Currency:
USD
Domicile:
United States

Classification & Risk

Asset Class:
Equity
Asset Region:
Global
Theme:
Thematic
Economic Development:
Global Markets
1 Year Volatility:
23.14%
3 Year Volatility:
23.46%
5 Year Volatility:
N/A

Performance

TTM Dividend Yield:
0.07% (verify with issuer)
1 Month Performance:
-2.14%
3 Month Performance:
-0.54%
6 Month Performance:
4.30%
1 Year Performance:
34.80%
3 Year Performance:
84.93%
5 Year Performance:
N/A
Investment Proposition

Tema Oncology ETF (CANC) delivers targeted access to the oncology ecosystem spanning drug developers, precision diagnostics, medical technology, and cancer care services. The approach emphasizes companies addressing prevention, detection, and treatment across tumor types, including platforms that enable next-generation modalities and companion testing. The strategy seeks long-term growth by concentrating on firms with durable scientific moats, scalable pipelines, and commercialization pathways, while recognizing the uneven cadence of trial readouts and regulatory events. Resulting exposures may tilt toward quality growth and innovation factors, with return dispersion influenced by data catalysts, competitive dynamics, and payer decisions. As a portfolio tool, CANC can act as a thematic satellite for allocators seeking cancer-specific innovation or as a completion sleeve within broader healthcare to deepen exposure to precision medicine. It tends to be supported when scientific validation accelerates and capital markets are constructive for development-stage companies, and challenged in risk-averse regimes or when reimbursement debates intensify. A fund-specific risk is pipeline clustering, where overlapping mechanisms or indications among holdings elevate correlation to single-theme outcomes.

ETF Analytics

Fund Discovery

4 Suggestions